Cardio Diagnostics Holdings, Inc. (CDIO)
Oxford Ledge is still expanding full research coverage of CDIO. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Cardio Diagnostics develops epigenetic-based blood tests to assess cardiovascular disease risk and improve prevention through precision medicine approaches.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 10-K Annual financial report with audited statements 2026-03-13
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-02-19
- 10-Q Quarterly financial report (unaudited) 2025-11-12
- 8-K Shareholder vote results; Financial statements and exhibits 2025-10-15
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for CDIO. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open CDIO in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.